This is a multicenter oen label study that will be conducted in patients 65 years of age and older requiring body computed tomography for diagnostic purposes, pre-operative evaluation, or post-operative evaluation. The areas to be examined will be the head, neck, thorax, abdomen, and/or pelvis. Patients will receive a single intravenous administration of Iomeprol 400 mgI/mL to assess the pharmockinetics, safety, and efficacy of this contrast agent. Approximately 20 patients will be enrolled in the study. Approximately 3 sites will enroll a minimum of 5 and up to a maximum of 15 patients. The method of sample size determination for the study can be dfound in the Statistical Analysis plan (Appendix K). Only patients meeting the eligibility criteria for this protocol will b eadmitted to this study. Study patients, if not currently inpatients, will b ehospitalized or stay in a speical study unit for 14 hours prior to dosing until 72 hours after dosing. A complete physical examination will be performed within 24 hours pre-dose and at 24 and 72 hours post-dose. Supine systolic and diastolic blood pressure, pulse rate, and respiratory rate will be recorded at the following time points: 15 and 10 munutes pre-dose, at 10, 30, and 60 minutes and 2, 4, 24, and 72 hours post-dose. Body temperature (0C), will be recorded at 15 and 10 minutes pre-dose, and at 1, 4, 24, and 72 hours post-dose. A 12-lead ECG will be taken and recorded within 24 hours pre-dose and 24 and 72 hours post-dose. Blood will be withdrawn, either by venipuncture or through an indwelling catheter, from a suitable periopheral vein. Blood draws of approximately 1 ml in volume will be collected to obtain Iomeprol levels in plasma at 5 minutes pre-dose and 5, 15, 30 and 45 minutes and 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours after completion of dosing. In addition, within 24 hours prior to dosing and 24 and 72 hours post-dose patients will also have blood taken for chemistry and hematology. The total blood volume withdrawn during the protocol period should not exceed approximately 30 mL. Urine will be collected at 12 to 0 hours pre-dose and 0 to 2, 2 to 4, 4 to 8, 8 to 16, 16 to 24, 24 to 36, 36 to 48, 48 to 60, and 60 to 72 hours post-dose.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
3M01RR001066-22S3
Application #
6265454
Study Section
Project Start
1998-12-01
Project End
1999-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
22
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Kelsey, Megan M; Braffett, Barbara H; Geffner, Mitchell E et al. (2018) Menstrual Dysfunction in Girls From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study. J Clin Endocrinol Metab 103:2309-2318
Kleinberger, Jeffrey W; Copeland, Kenneth C; Gandica, Rachelle G et al. (2018) Monogenic diabetes in overweight and obese youth diagnosed with type 2 diabetes: the TODAY clinical trial. Genet Med 20:583-590
Fourman, Lindsay T; Czerwonka, Natalia; Shaikh, Sofia D et al. (2018) Insulin-like growth factor 1 inversely relates to monocyte/macrophage activation markers in HIV. AIDS 32:927-932
Berkowitz, Robert I; Marcus, Marsha D; Anderson, Barbara J et al. (2018) Adherence to a lifestyle program for youth with type 2 diabetes and its association with treatment outcome in the TODAY clinical trial. Pediatr Diabetes 19:191-198
Arslanian, Silva; El Ghormli, Laure; Kim, Joon Young et al. (2018) The Shape of the Glucose Response Curve During an Oral Glucose Tolerance Test: Forerunner of Heightened Glycemic Failure Rates and Accelerated Decline in ?-Cell Function in TODAY. Diabetes Care :
Kriska, Andrea; El Ghormli, Laure; Copeland, Kenneth C et al. (2018) Impact of lifestyle behavior change on glycemic control in youth with type 2 diabetes. Pediatr Diabetes 19:36-44
Venditti, E M; Tan, K; Chang, N et al. (2018) Barriers and strategies for oral medication adherence among children and adolescents with Type 2 diabetes. Diabetes Res Clin Pract 139:24-31
Foldyna, Borek; Fourman, Lindsay T; Lu, Michael T et al. (2018) Sex Differences in Subclinical Coronary Atherosclerotic Plaque Among Individuals With HIV on Antiretroviral Therapy. J Acquir Immune Defic Syndr 78:421-428
Gidding, Samuel S; Bacha, Fida; Bjornstad, Petter et al. (2018) Cardiac Biomarkers in Youth with Type 2 Diabetes Mellitus: Results from the TODAY Study. J Pediatr 192:86-92.e5
Srinivasa, Suman; Lu, Michael T; Fitch, Kathleen V et al. (2018) Epicardial adipose tissue volume and cardiovascular risk indices among asymptomatic women with and without HIV. Antivir Ther 23:1-9

Showing the most recent 10 out of 945 publications